Hunt for 2013 Fierce 15 begins… Release the biotech hounds!

Calling everyone from the global biotech community. We've begun seeking nominations for FierceBiotech's 2013 class of Fierce 15 companies, and our editors would like to give readers a voice in the selection process. It's really easy: Just fill out our online nomination form here.

Our reader nominations have become a starting point in our search for 15 superb privately held companies from the biotech industry. The online form accompanies our editors' interactions with readers, entrepreneurs, investors and others to identify startups for the list. It's all about spotting ventures that rise above the rest of the biotech herd with compelling technologies, strategies and executive teams.

As is the nature for the biotech industry, we've seen Fierce 15 companies go on to big success and fail badly. Here's a winner from today's news: Pearl Therapeutics, which landed on our list in 2011, agreed to a $1.15 billion buyout deal with AstraZeneca ($AZN). 

While the online form is the best way to submit your nomination, we welcome people to share their thoughts about the Fierce 15 and worthy companies on Twitter with the #Fierce15 hash tag and/or on our LinkedIn group page, where I began a conversation this morning.

Here are the qualifications to be considered for FierceBiotech's Fierce 15:

  1. As previously noted, companies must be privately held, so no publicly traded companies, please.
  2. Companies should be engaged in advancing treatments for human diseases. This is not a list of agricultural bio or bio-fuel ventures.
  3. Company executives must be available for interviews and agree to keep their status in our selection process confidential until the final list is announced in September.

(FierceMedicalDevices has its own Fierce 15, which you can learn about here.)

For more than a decade, FierceBiotech's Fierce 15 has become one of the best ways for companies to raise their profiles and tell their stories to our global audience (find last year's report here). We write profiles on each of the selected companies, providing details on the technologies they are developing, the executives involved in the ventures and their plans for improving the treatment of diseases.

We feature the best biotech startups from around the world, not just from North America and Europe. We expect to spotlight more companies from emerging markets as more biotech startups take flight from them, and our online nomination form is a great way to put companies from outside biotech hubs in the West on our radar. Here's the online nomination form | Join our LinkedIn discussion

-- Ryan McBride (email | Twitter)

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.